Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bexxar tositumomab: Phase II data; BLA not acceptable for filing

Interim data from a Phase II trial of 38 previously untreated patients with low-grade or follicular NHL

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE